Resource Logo
NLM AIDSLINE

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA [see comments]




 

dine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE J Clin Invest.

JOURNAL ARTICLE MULTICENTER STUDY Adult Anti-HIV Agents/*ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Cohort Studies CD4 Lymphocyte Count/DRUG EFFECTS CD4-Positive T-Lymphocytes/PATHOLOGY Dideoxynucleosides/ADMINISTRATION & DOSAGE/PHARMACOLOGY/ THERAPEUTIC USE Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY/VIROLOGY HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/PHARMACOLOGY/ THERAPEUTIC USE HIV-1/*ISOLATION & PURIF HIV-1 Reverse Transcriptase/ANTAGONISTS & INHIB Lamivudine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Lymph Nodes/VIROLOGY Nelfinavir/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE/ PHARMACOLOGY/THERAPEUTIC USE RNA, Viral/*BLOOD Saquinavir/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Stavudine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Sulfonamides/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Support, Non-U.S. Gov't Time Factors *Viral Load Viremia/*DRUG THERAPY Zidovudine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE J Clin Invest. 2000 Mar;105(6):777-82. Unique Identifier : AIDSLINE MED/20193683



 




Information in this article was accurate in June 30, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.